Powder: -20°C for 3 years
In solvent: -80°C for 2 years
KD-026, a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.
Description | KD-026, a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies. |
Targets&IC50 | apolipoprotein B:9.6 nM, MTP:8.0 nM |
In vitro | KD-026 shows inhibitory effect against apolipoprotein B (IC50 = 9.6 nM) but no effect on apolipoprotein A1 secretion in Caco-2 cells[1]. |
In vivo | In rats, KD-026 (30 mg/kg) reduced postprandial lipids by 50% (ED50 = 7 mg/kg)[1]. |
Synonyms | SLx4090, SLx-4090, KD 026, SLx 4090, KD026 |
Molecular Weight | 546.54 |
Formula | C31H25F3N2O4 |
CAS No. | 913541-47-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 55 mg/ml (100.63 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KD-026 913541-47-6 代谢 CETP KD 026 microsomal triglyceride transfer protein MTP inhibitor KD026 SLx 4090 inhibit SLx-4090 Inhibitor enterocytic-specific dyslipidemia SLx4090 inhibitor